Preserved insulin secretory capacity and weight loss are the predominant predictors of glycemic control in patients with type 2 diabetes randomized to roux-en-y gastric bypass

Diabetes

Volumn 64, Issue 9, 2015, Pages 3104-3110

  Nguyen, Kim T ^a   Billington, Charles J ^b   Vella, Adrian ^c   Wang, Qi ^d   Ahmed, Leaque ^a   Bantle, John P ^b   Bessler, Marc ^a   Connett, John E ^d   Inabnet, William B ^e   Thomas, Avis ^d   Ikramuddin, Sayeed ^b   Korner, Judith ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; DIABETIC PATIENT; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN SENSITIVITY; INTENSIVE CARE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; WEIGHT REDUCTION; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS); STOMACH BYPASS; TREATMENT OUTCOME;

ADIPONECTIN; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC BYPASS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; OBESITY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84962839006     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1870     Document Type: Article

References (24)

1. Sjöström L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond) 2008;32(Suppl. 7):S93-S97
2. Nguyen KT, Korner J. The sum of many parts: potential mechanisms for improvement in glucose homeostasis after bariatric surgery. Curr Diab Rep 2014; 14:481
3. American Diabetes Association. Standards of medical care in diabetes-2015: summary of revisions. Diabetes Care 2015;38(Suppl.):S4
4. Dixon JB, Zimmet P, Alberti KG, Rubino F; International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery: an IDF statement for obese type 2 diabetes. Arq Bras Endocrinol Metabol 2011;55:367-382
5. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013;309:2240-2249
6. Thomas AJ, Bainbridge HA, Schone JL, et al. Recruitment and screening for a randomized trial investigating Roux-en-Y gastric bypass versus intensive medical management for treatment of type 2 diabetes. Obes Surg 2014;24:1875-1880
7. Polonsky KS, Licinio-Paixao J, Given BD, et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 1986;77:98-105
8. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 412-419
10. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
11. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 2008;16:1901-1907
12. Nguyen NQ, Debreceni TL, Bambrick JE, et al. Rapid gastric and intestinal transit is a major determinant of changes in blood glucose, intestinal hormones, glucose absorption and postprandial symptoms after gastric bypass. Obesity (Silver Spring) 2014;22:2003-2009
13. Nguyen NQ, Debreceni TL, Bambrick JE, et al. Upregulation of intestinal glucose transporters after Roux-en-Y gastric bypass to prevent carbohydrate malabsorption. Obesity (Silver Spring) 2014;22:2164-2171
14. Jørgensen NB, Dirksen C, Bojsen-Møller KN, et al. Exaggerated glucagon-like peptide 1 response is important for improved b-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 2013;62:3044-3052
15. Bojsen-Møller KN, Dirksen C, Jørgensen NB, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 2014;63:1725-1737
16. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007;3:597-601
17. Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:2479-2485
18. Dutia R, Brakoniecki K, Bunker P, et al. Limited recovery of b-cell function after gastric bypass despite clinical diabetes remission. Diabetes 2014;63:1214-1223
19. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011;60:2308-2314
20. Habegger KM, Heppner KM, Amburgy SE, et al. GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats. Diabetes 2014;63:505-513
21. Camastra S, Muscelli E, Gastaldelli A, et al. Long-term effects of bariatric surgery on meal disposal and b-cell function in diabetic and nondiabetic patients. Diabetes 2013;62:3709-3717
22. Holst JJ, Pedersen JH, Baldissera F, Stadil F. Circulating glucagon after total pancreatectomy in man. Diabetologia 1983;25:396-399
23. Drucker DJ. Glucagon-like peptide 2. J Clin Endocrinol Metab 2001;86: 1759-1764
24. Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 2011;300:E1038-E1046